Who are Vaginal TFV Gel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Regimen:TDF+3TC+EFV, DTG/3TC/ABC + ELV/COBI/FTC/TAF, didanosine + lamivudine + efavirenz, Didanosine (enteric-coated), Lamivudine / Abacavir Sulfate, AZT+3TC+ABV (Trizivir).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vaginal-tfv-gel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Vaginal TFV Gel — Competitive Intelligence Brief

Vaginal TFV Gel (Vaginal TFV Gel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleotide reverse transcriptase inhibitor (microbicide). Area: Infectious Disease / HIV Prevention.

marketed Nucleotide reverse transcriptase inhibitor (microbicide) HIV reverse transcriptase Infectious Disease / HIV Prevention Small molecule Live · refreshed every 30 min

Target snapshot

Vaginal TFV Gel (Vaginal TFV Gel) — University of Washington. Tenofovir (TFV) gel applied vaginally blocks HIV reverse transcriptase to prevent sexual transmission of HIV.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Vaginal TFV Gel TARGET	Vaginal TFV Gel	University of Washington	marketed	Nucleotide reverse transcriptase inhibitor (microbicide)	HIV reverse transcriptase
Regimen:TDF+3TC+EFV	Regimen:TDF+3TC+EFV	National Center for AIDS/STD Control and Prevention, China CDC	marketed	Antiretroviral combination therapy (NRTI + NNRTI)	HIV reverse transcriptase
DTG/3TC/ABC + ELV/COBI/FTC/TAF	DTG/3TC/ABC + ELV/COBI/FTC/TAF	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
didanosine + lamivudine + efavirenz	didanosine + lamivudine + efavirenz	Clinical Trial Agency of HIV Study Group	marketed	Antiretroviral combination therapy (NRTI + NNRTI)	HIV reverse transcriptase
Didanosine (enteric-coated)	Didanosine (enteric-coated)	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase
Lamivudine / Abacavir Sulfate	Lamivudine / Abacavir Sulfate	GlaxoSmithKline	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
AZT+3TC+ABV (Trizivir)	AZT+3TC+ABV (Trizivir)	Fundacion SEIMC-GESIDA	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleotide reverse transcriptase inhibitor (microbicide) class)

University of Washington · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vaginal TFV Gel — Competitive Intelligence Brief. https://druglandscape.com/ci/vaginal-tfv-gel. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab